肺炎球菌ワクチン市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、適応症別、製品別、流通別、地域別、競合別、2020-2030F

肺炎球菌ワクチンの世界市場規模は2024年に96億3,000万米ドルとなり、予測期間では2030年までCAGR 6.26%で目覚ましい成長が予測されています。

世界の肺炎球菌ワクチン市場は、医薬品・ヘルスケア産業の重要なセグメントであり、主に肺炎球菌による感染症の予防を目的としています。肺炎球菌感染症は、肺炎、髄膜炎、敗血症など様々な病気を引き起こす可能性があり、特に幼児や高齢者にとっては公衆衛生上の重大な脅威となっています。例えば、WHOの2023年の推計によると、肺炎球菌感染症は毎年世界中で約160万人の死亡を引き起こし、そのうち100万人近くが5歳未満の小児で死亡しています。子どもの死亡率に大きな影響を与えることから、WHOは肺炎球菌感染症をワクチン接種の優先度の高い疾患としています。これに対抗するため、WHOは効果的な予防策として13価肺炎球菌結合型ワクチン（PCV）の使用を強く推奨しています。これらのワクチンは、特にヘルスケアへのアクセスが限られ、疾病の蔓延率が高い地域において、幼児における肺炎、髄膜炎、敗血症などの重症感染症を減少させる上で重要な役割を果たしています。

市場促進要因

肺炎球菌感染症に対する世界の意識の高まり

主な市場課題

経済格差

主要市場動向

次世代ワクチン

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の肺炎球菌ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 種類別（結合ワクチン、多糖体ワクチン）
  • 適応症別（気管支炎、髄膜炎、肺炎、敗血症）
  • 製品別（Pneumovax23、Prevnar 13、Synflorix）
  • 分布別（政府機関、非政府組織）
  • 地域別
  • 企業別（2024）
• 製品市場マップ
  • タイプ別
  • 適応症別
  • 製品別
  • 配布先別
  • 地域別

第6章 北米の肺炎球菌ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の肺炎球菌ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域の肺炎球菌ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の肺炎球菌ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの肺炎球菌ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• GSK PLC
• Pfizer Inc
• Merck KGaA
• Serum Institute of India Pvt Ltd
• CSL Ltd
• Sanofi SA
• Walvax Biotechnology Co., Ltd
• Beijing Minhai Biotechnology Limited Company
• AstraZeneca PLC
• BioNTech

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Pneumococcal Vaccine Market was valued at USD 9.63 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.26% through 2030. The global pneumococcal vaccine market is a crucial segment of the pharmaceutical and healthcare industry, primarily aimed at preventing infections caused by Streptococcus pneumoniae bacteria. Pneumococcal infections can lead to various illnesses, including pneumonia, meningitis, and sepsis, and they pose a significant public health threat, particularly to young children and the elderly. For instance, according to WHO estimates in 2023, pneumococcal infections cause approximately 1.6 million deaths worldwide each year, with nearly one million fatalities occurring in children under the age of five. Given its significant impact on child mortality, WHO classifies pneumococcal disease as a high-priority condition for vaccination. To combat this, the organization strongly recommends the use of 13-valent pneumococcal conjugate vaccines (PCVs) as an effective preventive measure. These vaccines play a crucial role in reducing severe infections such as pneumonia, meningitis, and sepsis in young children, particularly in regions with limited healthcare access and high disease prevalence.

Key Market Drivers

Rising Global Awareness of Pneumococcal Diseases

One of the fundamental reasons behind the growth of the pneumococcal vaccine market is the increasing understanding of the serious health consequences posed by pneumococcal diseases. Medical professionals, policymakers, and the general public are becoming more aware of the debilitating and potentially fatal nature of these infections, leading to a heightened sense of urgency in preventing them. For instance, in June 2023, Sanofi and SK bioscience announced positive results from phase II clinical trials of their 21-valent conjugate vaccine candidate. The findings suggest that GBP410 may provide broader serotype coverage compared to existing vaccines, potentially expanding its market share. Based on these promising results, the companies plan to advance to phase III trials in 2024, with the goal of obtaining final data by 2027.

Public health organizations and advocacy groups have played a pivotal role in disseminating information about pneumococcal diseases. Their efforts include educational campaigns, public service announcements, and initiatives that emphasize the importance of vaccination. As individuals become better informed, they are more likely to seek out and request pneumococcal vaccines.

Key Market Challenges

Economic Disparities

One of the most prominent challenges is the economic disparity among nations. High-income countries often have better access to pneumococcal vaccines due to robust healthcare infrastructures and funding. In contrast, low- and middle-income countries struggle to afford these vaccines, leading to unequal access and health disparities.

Key Market Trends

Next-Generation Vaccines

Advancements in vaccine technology are paving the way for next-generation pneumococcal vaccines. These vaccines are designed to offer broader protection against a wider range of pneumococcal serotypes. By harnessing innovative formulations and targeting evolving bacterial strains, next-gen vaccines are poised to enhance vaccine effectiveness and durability.

Key Market Players

• GSK PLC
• Pfizer Inc
• Merck KGaA
• Serum Institute of India Pvt Ltd
• CSL Ltd
• Sanofi SA
• Walvax Biotechnology Co., Ltd
• Beijing Minhai Biotechnology Limited Company
• AstraZeneca PLC
• BioNTech

Report Scope:

In this report, the Global Pneumococcal Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pneumococcal Vaccine Market, By Type:

• Conjugate Vaccines
• Polysaccharide Vaccines

Pneumococcal Vaccine Market, By Indication:

• Bronchitis
• Meningitis
• Pneumonia
• Sepsis

Pneumococcal Vaccine Market, By Product:

• Pneumovax23
• Prevnar 13
• Synflorix

Pneumococcal Vaccine Market, By Distribution:

• Government Authorities
• Non-Governmental Organizations

Pneumococcal Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pneumococcal Vaccine Market.

Available Customizations:

Global Pneumococcal Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pneumococcal Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 5.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 5.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 5.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Type
  • 5.3.2. By Indication
  • 5.3.3. By Product
  • 5.3.4. By Distribution
  • 5.3.5. By Region

6. North America Pneumococcal Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 6.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 6.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 6.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pneumococcal Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By Distribution
  • 6.3.2. Canada Pneumococcal Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By Distribution
  • 6.3.3. Mexico Pneumococcal Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By Distribution

7. Europe Pneumococcal Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 7.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 7.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 7.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pneumococcal Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By Distribution
  • 7.3.2. United Kingdom Pneumococcal Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By Distribution
  • 7.3.3. France Pneumococcal Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By Distribution
  • 7.3.4. Italy Pneumococcal Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By Distribution
  • 7.3.5. Spain Pneumococcal Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By Distribution

8. Asia-Pacific Pneumococcal Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 8.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 8.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 8.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pneumococcal Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By Distribution
  • 8.3.2. Japan Pneumococcal Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By Distribution
  • 8.3.3. India Pneumococcal Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By Distribution
  • 8.3.4. Australia Pneumococcal Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By Distribution
  • 8.3.5. South Korea Pneumococcal Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By Distribution

9. South America Pneumococcal Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 9.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 9.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 9.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pneumococcal Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By Distribution
  • 9.3.2. Argentina Pneumococcal Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By Distribution
  • 9.3.3. Colombia Pneumococcal Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By Distribution

10. Middle East and Africa Pneumococcal Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 10.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 10.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 10.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pneumococcal Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By Distribution
  • 10.3.2. Saudi Arabia Pneumococcal Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By Distribution
  • 10.3.3. UAE Pneumococcal Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By Distribution
  • 10.3.4. Kuwait Pneumococcal Vaccine Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By Indication
      • 10.3.4.2.3. By Product
      • 10.3.4.2.4. By Distribution

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. GSK PLC
  • 14.1.1. Business Overview
  • 14.1.2. Product Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Pfizer Inc
• 14.3. Merck KGaA
• 14.4. Serum Institute of India Pvt Ltd
• 14.5. CSL Ltd
• 14.6. Sanofi SA
• 14.7. Walvax Biotechnology Co., Ltd
• 14.8. Beijing Minhai Biotechnology Limited Company
• 14.9. AstraZeneca PLC
• 14.10. BioNTech

15. Strategic Recommendations

16. About Us & Disclaimer